Eli Lilly and Company (LLY)
These stocks join Meta and Eli Lilly as the biggest winners this earnings season
We're nearing the end of second-quarter earnings season, so this is a good moment to screen the S&P 500 and show which companies increased revenue the most while also improving their profit margins.
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Obesity drugmakers like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO were not immune to the broad market sell-off sparked by the June CPI report, but investors looking to get into these names should be cheering. The stocks are down 20% or more from their highs, offering big discounts and the opportunity for fat profits over the long term.
After Eli Lilly's blowout quarter, Cramer says not to get too caught up in macro market trends
CNBC's Jim Cramer on Thursday recommended that investors not base portfolio decisions solely off of macro economic trends, like new employment data or interest rates. He discussed pharmaceutical giant Eli Lilly's blow-out quarter, saying its success is not due to general attitudes on the market.
S&P 500 Gains and Losses Today: Eli Lilly Soars on Growing Demand for Weight-Loss Drugs
Major U.S. equities indexes rallied after jobless claims data released Thursday helped ease worries about the economy. The S&P 500 jumped 2.3%, marking the strongest daily performance for the benchmark index since November 2022.
4 Key Takeaways From Eli Lilly's Earnings
Eli Lilly (LLY) shares soared Thursday, after the company's second-quarter earnings surpassed expectations on booming demand for its weight-loss drugs and executives provided updates on production capacity and more.
Eli Lilly: The Next $1 Trillion Market Cap Stock?
Eli Lilly ( LLY ) reported strong quarterly results on Thursaday morning, with revenue increasing 36%, driven primarily by the success of Mounjaro, Zepbound, and Verzenio. The company also saw a significant increase in earnings per share (EPS), up 68% year-on-year and eclipsing analysts' estimates by 42%.
Why Eli Lilly Stock Just Jumped 8%
Powered by Mounjaro and Zepbound, Lilly announced staggering sales and earnings growth this morning. The weight loss drug business is so good, Lilly also raised its full-year sales forecast by $3 billion.
Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Eli Lilly raises forecast after boost in Zepbound, Mounjaro sales
Eli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.
Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter
Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Options Bulls Target Eli Lilly Stock After Beat-and-Raise
Eli Lilly And Co (NYSE:LLY) surpassed top- and bottom-line expectations for the second quarter, and lifted its full-year revenue outlook by $3 billion amid strong sales of weight loss drug and diabetes drugs Zepbound and Mounjaro.
